RxDoctor Payments Data

Larry Diaz, MD

Cardiovascular Disease · Wyoming, MINPI 1952301038

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by Penumbra, Inc. at 38.8% of the total. Reporting peaked in 2019 at $10,216 and has fallen 81.6% since, to $1,876 in 2025.

$32,720in general payments, 2019–2025

Across 237 payments — averaging $138.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$13K
  • Cook Incorporated$9K
  • Medicure Pharma Inc.$2K
  • Boston Scientific$1K
  • Abiomed$855
  • Abbott$728
  • plus $7K from 39 others
$268,652in research payments, 2019–2025

Across 88 payments — averaging $3052.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cardiovascular Systems Inc.$104K
  • Penumbra, Inc.$66K
  • Bard Peripheral Vascular, Inc.$43K
  • Bayer$18K
  • EKOS Corporation$17K
  • Philips North America LLC$9K
  • plus $11K from 2 others

What the payments were for

  • Consulting fees$1,6005%
  • Speaking & faculty fees$16,20550%
  • Travel & lodging$3,39310%
  • Food & beverage$11,52135%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,720 in reported general payments places this provider in the 85th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$91,129
Medicare patients
508
Services billed
1,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban233$230,495
JardianceEmpagliflozin99$118,515
EntrestoSacubitril/Valsartan65$75,745
XareltoRivaroxaban39$50,971
Repatha SureclickEvolocumab39$38,842
Praluent PenAlirocumab14$12,362
Metoprolol Succinate593$10,367
Atorvastatin Calcium491$7,980
Prasugrel Hcl89$6,298
Ezetimibe198$5,489
Verapamil SrVerapamil Hcl29$4,820
Torsemide117$2,433
Midodrine Hcl15$2,057
Amlodipine Besylate212$1,957
Spironolactone166$1,924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$202$230,495233 claims
Boehringer IngelheimJardiance$43$118,51599 claims
NovartisEntresto$484$75,74565 claims
Johnson & JohnsonXarelto$384$50,97139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Wyoming

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →